Dr. Torres is a consultant for Gilead Sciences; Merck & Co., Inc.; Novartis; Astellas Pharma; Pfizer Inc.; Theravance Biopharma, Inc.; Genentech Inc.; and Vertex Pharmaceuticals, and received research grants from Merck & Co., Inc. and Vertex Pharmaceuticals. Dr. Kontoyiannis is a consultant for Merck & Co., Inc., a member of a speaker’s bureau of Merck & Co., Inc.; Gilead Sciences; and Pfizer Inc., and received research grants from Merck & Co., Inc.; Astellas Pharma; and Pfizer Inc. All other authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
The results of this study were presented in part at the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1–5, 2013; Washington, DC.
Author contributions: Dr. Torres designed the study, provided study patients, analyzed and interpreted the data, and wrote the manuscript; Dr. Mahale performed research, analyzed and interpreted the data, performed statistical analysis, designed tables and figures, and wrote the manuscript; Drs. Blechacz, Miller, Herlong, Kaseb, Fowler, Raad, and Kontoyiannis provided patients, analyzed and interpreted the data, and wrote the manuscript; and Dr. Jiang analyzed and interpreted the data, and performed statistical analyses.
The authors would like to thank Ann Sutton for editorial assistance.
Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012;55(Suppl 1):S10–15.
Smith BD, Morgan RL, Beckett GA. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61(RR-4):1–32.
Lee MH, Yang HI, Lu SN. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469–477.
Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;46:2925–2930.
Faggioli P, De Paschale M, Tocci A. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin’s lymphoma. Haematologica 1997;82:38–42.
Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333–340.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374.
Huang CF, Huang JF, Chen WC. The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. Hepatol Int 2013;7:180–187.
Peffault de Latour R, Levy V, Asselah T. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004;103:1618–1624.
Peffault de Latour R, Asselah T, Levy V. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005;36:709–713.
Ljungman P, Locasciulli A, de Soria VG. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant 2012;47:1217–1221.
Allison RD. Increased risk of extra-hepatic cancer mortality among persons with chronic hepatitis C infection. Presented at: Annual meeting of the American College of Preventive Medicine; February 19-22, 2014; New Orleans, Louisiana.
Locasciulli A, Alberti A. Hepatitis C virus serum markers and liver disease in children with leukemia. Leuk Lymphoma 1995;17:245–249.
Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012;9:156–166.
Mira JA, Rivero-Juarez A, Lopez-Cortes LF. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013;56:1646–1653.
Tomblyn M, Chiller T, Einsele H. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143–1238.
Ramos CA, Saliba RM, de Padua L. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009;94:249–257.
Torres HA, Adachi JA, Roach LR. Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: help is on the way. Clin Infect Dis 2012;54:740–742.
Davila JA, Morgan RO, Shaib Y. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372–1380.
Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology 2003;125:1723–1732.
Antonelli A, Ferri C, Fallahi P. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007;17:447–451.
Donelli MG, Zucchetti M, Munzone E. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34:33–46.
Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis—a practical guide. Aliment Pharmacol Ther 2013;37:1132–1156.
Manns MP, McHutchison JG, Gordon SC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–965.
American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://hcvguidelines.org/. Accessed March 28, 2014.
Ascierto PA, Gogas HJ, Grob JJ. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit Rev Oncol Hematol 2013;85:149–161.
Talpaz M, Hehlmann R, Quintas-Cardama A. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia 2013;27:803–812.
Mahale P, Kontoyiannis DP, Chemaly RF. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012;57:1177–1185.
Morgan RL, Baack B, Smith BD. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329–337.
Miyatake H, Kobayashi Y, Iwasaki Y. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2012;57:1092–1101.
Breitenstein S, Dimitroulis D, Petrowsky H. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009;96:975–981.
Safdar A. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist 2007;12(Suppl 2):2–6.
Klingemann HG, Grigg AP, Wilkie-Boyd K. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. Blood 1991;78:3306–3311.